Physician profile
Karalee Bessinger
NPI 1891938718
$458.26
in general payments reported to CMS, 2019-2025
15 companies · $274 in 2025
The $274 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $184 · 2025: $274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $458.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $458.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $138.57 | 2024-2025 | |
| Vanda Pharmaceuticals INC. | $60.59 | 2024-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.48 | 2024-2025 | Caplyta |
| Exact Sciences Corporation | $33.38 | 2024 | Cologuard Collection Kit |
| Amgen INC. | $29.98 | 2025 | Otezla, Repatha |
| Novo Nordisk INC | $21.80 | 2025 | Ozempic, Rybelsus |
| Antares Pharma, INC. | $18.44 | 2025 | Xyosted |
| Ultragenyx Pharmaceutical INC. | $17.38 | 2024 | Crysvita |
| Glaxosmithkline, LLC. | $17.32 | 2025 | Arexvy, Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $14.98 | 2025 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $14.74 | 2025 | Zoryve |
| Dynavax Technologies Corporation | $14.71 | 2025 | Heplisav-B |
| Astrazeneca Pharmaceuticals LP | $14.60 | 2024 | Airsupra |
| Medtronic, INC. | $13.70 | 2025 | Minimed 780g |
| Lilly USA, LLC | $13.59 | 2025 | Mounjaro, Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karalee Bessinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.